Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment

potential role as markers of response to antiviral therapy

Giuseppe Murdaca, Paola Contini, Paola Cagnati, Simona Marenco, Giulia Pieri, Francesca Lantieri, Antonino Picciotto, Francesco Puppo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The serum levels of soluble HLA class I antigens (sHLA-A, -B, -C and sHLA-G) were determined in 40 HCV genotype 1-infected patients before (T0), after 3, 6, and 12 months (T3, T6, and T12) of pegylated-IFN-α plus ribavirin therapy and 6 months (T18) after the end of treatment. Twenty patients were sustained virological responders (SVR), and 20 were non-responders (NR). sHLA-A, -B, -C levels at T0 were significantly higher in both SVR (mean 10.48 μg/ml) and NR (mean 11.87 μg/ml) patients as compared to healthy controls (mean 0.34 μg/ml, p <0.0001) and HIV-infected subjects (mean 1.22 μg/ml, p <0.0001). sHLA-G levels at T0 were significantly higher in SVR (mean 24.78 ng/ml) and NR (mean 24.93 ng/ml) patients as compared to healthy controls (mean 10.34 ng/ml, p = 0.015 and p = 0.014, respectively) but were lower as compared to HIV-infected subjects (mean 48.00 ng/ml, p <0.0001). The levels of sHLA-A, -B, -C and sHLA-G significantly decreased in SVR from T0 to T18 (mean 1.64 and 1.43 ng/ml, respectively, p <0.0001) and correlated with HCV-RNA, AST, ALT, γGT, and ALP levels. The determination of soluble HLA class I levels could be proposed as a surrogate marker to discriminate SVR and NR HCV-infected patients during PEG-IFN-α plus ribavirin therapy.

Original languageEnglish
JournalClinical and Experimental Medicine
DOIs
Publication statusAccepted/In press - Nov 14 2015

Fingerprint

HLA-G Antigens
HLA-A Antigens
HLA-B Antigens
Ribavirin
Chronic Hepatitis C
Virus Diseases
Viruses
Hepacivirus
Interferons
Antiviral Agents
Histocompatibility Antigens Class I
Molecules
Polyethylene glycols
RNA
HIV
Therapeutics
HLA Antigens
Biomarkers
Genotype
Serum

Keywords

  • HCV
  • HLA-G
  • Interferon-α
  • Ribavirin
  • Soluble HLA

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment : potential role as markers of response to antiviral therapy. / Murdaca, Giuseppe; Contini, Paola; Cagnati, Paola; Marenco, Simona; Pieri, Giulia; Lantieri, Francesca; Picciotto, Antonino; Puppo, Francesco.

In: Clinical and Experimental Medicine, 14.11.2015.

Research output: Contribution to journalArticle

@article{65a77ab6d44f483b97d81fb10a565b64,
title = "Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy",
abstract = "The serum levels of soluble HLA class I antigens (sHLA-A, -B, -C and sHLA-G) were determined in 40 HCV genotype 1-infected patients before (T0), after 3, 6, and 12 months (T3, T6, and T12) of pegylated-IFN-α plus ribavirin therapy and 6 months (T18) after the end of treatment. Twenty patients were sustained virological responders (SVR), and 20 were non-responders (NR). sHLA-A, -B, -C levels at T0 were significantly higher in both SVR (mean 10.48 μg/ml) and NR (mean 11.87 μg/ml) patients as compared to healthy controls (mean 0.34 μg/ml, p <0.0001) and HIV-infected subjects (mean 1.22 μg/ml, p <0.0001). sHLA-G levels at T0 were significantly higher in SVR (mean 24.78 ng/ml) and NR (mean 24.93 ng/ml) patients as compared to healthy controls (mean 10.34 ng/ml, p = 0.015 and p = 0.014, respectively) but were lower as compared to HIV-infected subjects (mean 48.00 ng/ml, p <0.0001). The levels of sHLA-A, -B, -C and sHLA-G significantly decreased in SVR from T0 to T18 (mean 1.64 and 1.43 ng/ml, respectively, p <0.0001) and correlated with HCV-RNA, AST, ALT, γGT, and ALP levels. The determination of soluble HLA class I levels could be proposed as a surrogate marker to discriminate SVR and NR HCV-infected patients during PEG-IFN-α plus ribavirin therapy.",
keywords = "HCV, HLA-G, Interferon-α, Ribavirin, Soluble HLA",
author = "Giuseppe Murdaca and Paola Contini and Paola Cagnati and Simona Marenco and Giulia Pieri and Francesca Lantieri and Antonino Picciotto and Francesco Puppo",
year = "2015",
month = "11",
day = "14",
doi = "10.1007/s10238-015-0399-5",
language = "English",
journal = "Zeitschrift für Die Gesamte Experimentelle Medizin",
issn = "1591-8890",
publisher = "Springer-Verlag Italia",

}

TY - JOUR

T1 - Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment

T2 - potential role as markers of response to antiviral therapy

AU - Murdaca, Giuseppe

AU - Contini, Paola

AU - Cagnati, Paola

AU - Marenco, Simona

AU - Pieri, Giulia

AU - Lantieri, Francesca

AU - Picciotto, Antonino

AU - Puppo, Francesco

PY - 2015/11/14

Y1 - 2015/11/14

N2 - The serum levels of soluble HLA class I antigens (sHLA-A, -B, -C and sHLA-G) were determined in 40 HCV genotype 1-infected patients before (T0), after 3, 6, and 12 months (T3, T6, and T12) of pegylated-IFN-α plus ribavirin therapy and 6 months (T18) after the end of treatment. Twenty patients were sustained virological responders (SVR), and 20 were non-responders (NR). sHLA-A, -B, -C levels at T0 were significantly higher in both SVR (mean 10.48 μg/ml) and NR (mean 11.87 μg/ml) patients as compared to healthy controls (mean 0.34 μg/ml, p <0.0001) and HIV-infected subjects (mean 1.22 μg/ml, p <0.0001). sHLA-G levels at T0 were significantly higher in SVR (mean 24.78 ng/ml) and NR (mean 24.93 ng/ml) patients as compared to healthy controls (mean 10.34 ng/ml, p = 0.015 and p = 0.014, respectively) but were lower as compared to HIV-infected subjects (mean 48.00 ng/ml, p <0.0001). The levels of sHLA-A, -B, -C and sHLA-G significantly decreased in SVR from T0 to T18 (mean 1.64 and 1.43 ng/ml, respectively, p <0.0001) and correlated with HCV-RNA, AST, ALT, γGT, and ALP levels. The determination of soluble HLA class I levels could be proposed as a surrogate marker to discriminate SVR and NR HCV-infected patients during PEG-IFN-α plus ribavirin therapy.

AB - The serum levels of soluble HLA class I antigens (sHLA-A, -B, -C and sHLA-G) were determined in 40 HCV genotype 1-infected patients before (T0), after 3, 6, and 12 months (T3, T6, and T12) of pegylated-IFN-α plus ribavirin therapy and 6 months (T18) after the end of treatment. Twenty patients were sustained virological responders (SVR), and 20 were non-responders (NR). sHLA-A, -B, -C levels at T0 were significantly higher in both SVR (mean 10.48 μg/ml) and NR (mean 11.87 μg/ml) patients as compared to healthy controls (mean 0.34 μg/ml, p <0.0001) and HIV-infected subjects (mean 1.22 μg/ml, p <0.0001). sHLA-G levels at T0 were significantly higher in SVR (mean 24.78 ng/ml) and NR (mean 24.93 ng/ml) patients as compared to healthy controls (mean 10.34 ng/ml, p = 0.015 and p = 0.014, respectively) but were lower as compared to HIV-infected subjects (mean 48.00 ng/ml, p <0.0001). The levels of sHLA-A, -B, -C and sHLA-G significantly decreased in SVR from T0 to T18 (mean 1.64 and 1.43 ng/ml, respectively, p <0.0001) and correlated with HCV-RNA, AST, ALT, γGT, and ALP levels. The determination of soluble HLA class I levels could be proposed as a surrogate marker to discriminate SVR and NR HCV-infected patients during PEG-IFN-α plus ribavirin therapy.

KW - HCV

KW - HLA-G

KW - Interferon-α

KW - Ribavirin

KW - Soluble HLA

UR - http://www.scopus.com/inward/record.url?scp=84946924431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946924431&partnerID=8YFLogxK

U2 - 10.1007/s10238-015-0399-5

DO - 10.1007/s10238-015-0399-5

M3 - Article

JO - Zeitschrift für Die Gesamte Experimentelle Medizin

JF - Zeitschrift für Die Gesamte Experimentelle Medizin

SN - 1591-8890

ER -